Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Atrial Fibrillation (AF) and Ibrutinib, a Monocentric Experience: Should Cardiological Evaluation be a Guide in Clinical Practice?

Gianluigi Reda, MD, Ramona Cassin, Veronica Mattiello, Tatiana Tonella, Diana Giannarelli, PhD, Bruno Fattizzo, MD, Francesco Onida, MD, Ferdinando Maria Massari, Agostino Cortelezzi, Prof

Blood (2017) 130 (Supplement 1): 1747.

https://doi.org/10.1182/blood.V130.Suppl_1.1747.1747

Published: 2017

Journal Articles

Effective Treatment of Severe Chronic Graft Versus Host Disease with a Combination of B-Cell Depletion and Tyrosine Kinase Inhibition

Lotte E. van der Wagen, MD, Liane te Boome, MD, Inger Nijhof, MD, Marieke Schoordijk, Ellen Meijer, MD PhD, Jurgen Kuball, MD PhD

Blood (2016) 128 (22): 4565.

https://doi.org/10.1182/blood.V128.22.4565.4565

Published: 2016

Journal Articles

Cardiac Safety of One Versus Four Hour Romidepsin (Istodax®) Infusion In the Setting of a Phase I/II Trial of Romidepsin, Dexamethasone and Bortezomib for Relapsed or Refractory Multiple Myeloma

Sam A Ruell, RN, Miles Prince, MD, FRACP, FRCPA, Hang Quach, MBBS, FRACP, FRCPA, MD, Emma Link, PhD, Joanne Dean, Simon J. Harrison, MD, PhD

Blood (2010) 116 (21): 5037.

https://doi.org/10.1182/blood.V116.21.5037.5037

Published: 2010

Journal Articles

A Phase I Study of Midostaurin (PKC412) Investigating Cardiac Interval Effects In Healthy Subjects

Adam del Corral, Catherine Dutreix, Alice Huntsman Labed, Sumita Rai, Kai Grosch, Joel Morganroth, Robert Harrell, Jr., Yanfeng Wang

Blood (2010) 116 (21): 4362.

https://doi.org/10.1182/blood.V116.21.4362.4362

Published: 2010

Journal Articles

QT Interval Measurements in Patients with Hematologic Malignancies and Solid Tumors Treated with Oral Panobinostat (LBH589).

Harald A. Weber, MD, Feng Tai, PhD, Sofia Paul, PhD, Joanne Schindler, Margaret M. Woo, Stan Spence, PhD, Jennifer Marlowe, Rong Lin, MD

Blood (2009) 114 (22): 3781.

https://doi.org/10.1182/blood.V114.22.3781.3781

Published: 2009

Journal Articles

High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party

Blood (2008) 112 (11): 181.

https://doi.org/10.1182/blood.V112.11.181.181

Published: 2008

Journal Articles

Use of Arsenic Trioxide in Acute Promyelocytic Leukemia Leads to Cardiotoxicity in African-American Patients.

Sandip P. Patel, BS, Elihu H. Estey, MD

Blood (2005) 106 (11): 896.

https://doi.org/10.1182/blood.V106.11.896.896

Published: 2005

NARROW

Atrial Fibrillation (AF) and Ibrutinib, a Monocentric Experience: Should Cardiological Evaluation be a Guide in Clinical Practice?

Effective Treatment of Severe Chronic Graft Versus Host Disease with a Combination of B-Cell Depletion and Tyrosine Kinase Inhibition

Cardiac Safety of One Versus Four Hour Romidepsin (Istodax®) Infusion In the Setting of a Phase I/II Trial of Romidepsin, Dexamethasone and Bortezomib for Relapsed or Refractory Multiple Myeloma

A Phase I Study of Midostaurin (PKC412) Investigating Cardiac Interval Effects In Healthy Subjects

QT Interval Measurements in Patients with Hematologic Malignancies and Solid Tumors Treated with Oral Panobinostat (LBH589).

High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party

Use of Arsenic Trioxide in Acute Promyelocytic Leukemia Leads to Cardiotoxicity in African-American Patients.

Email alerts

ASH Publications

American Society of Hematology

Atrial Fibrillation (AF) and Ibrutinib, a Monocentric Experience: Should Cardiological Evaluation be a Guide in Clinical Practice?

Effective Treatment of Severe Chronic Graft Versus Host Disease with a Combination of B-Cell Depletion and Tyrosine Kinase Inhibition

Cardiac Safety of One Versus Four Hour Romidepsin (Istodax®) Infusion In the Setting of a Phase I/II Trial of Romidepsin, Dexamethasone and Bortezomib for Relapsed or Refractory Multiple Myeloma

A Phase I Study of Midostaurin (PKC412) Investigating Cardiac Interval Effects In Healthy Subjects

QT Interval Measurements in Patients with Hematologic Malignancies and Solid Tumors Treated with Oral Panobinostat (LBH589).

High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party

Use of Arsenic Trioxide in Acute Promyelocytic Leukemia Leads to Cardiotoxicity in African-American Patients.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only